Biomarkers and prognostic factors of PD-1/PD-L1 inhibitor-based therapy in patients with advanced hepatocellular carcinoma
Nan Zhang(North China University of Science and Technology), Haitao Zhao(Chinese Academy of Medical Sciences & Peking Union Medical College), Hanping Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Zhenhui Lu(Guangxi Medical University), Ziyu Xun(Chinese Academy of Medical Sciences & Peking Union Medical College), Longhao Zhang(Chinese Academy of Medical Sciences & Peking Union Medical College), Xinmu Zhang(Brigham and Women's Hospital), Shanshan Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Yang Xu(Washington State University), Yanyu Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Mingjian Piao(Chinese Academy of Medical Sciences & Peking Union Medical College), Xiaobo Yang(Chinese Academy of Medical Sciences & Peking Union Medical College), Jiashuo Chao(Chinese Academy of Medical Sciences & Peking Union Medical College), Yunchao Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Cong Ning(Chinese Academy of Medical Sciences & Peking Union Medical College)
Cited by 82
Related Papers
Evaluation of cell-free DNA approaches for multi-cancer early detection
|Cancer Cell|2022|311
Signaling pathways in cancer metabolism: mechanisms and therapeutic targets
|Signal Transduction and Targeted Therapy|2023|289
Phosphorylation stabilizes Nanog by promoting its interaction with Pin1
|Proceedings of the National Academy of Sciences|2010|149
Therapeutic potential of a fully human monoclonal antibody against influenza A virus M2 protein
|Antiviral Research|2008|144